Seek Returns

Gilead Sciences (GILD) Stock Analysis

This is a peer-relative look at Gilead Sciences (GILD): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

Company profile fields for Gilead Sciences (GILD)
Profile ItemGILD
NameGilead Sciences Inc.
Country/RegionUnited States
GICS SectorHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
GICS Sub-IndustryBiotechnology
Market Capitalization207.00 billion USD
CurrencyUSD
ExchangeNasdaq
Listing DateJanuary 22, 1992
Security TypeCommon Stock

Price Performance

Cumulative Growth

GILD
GSPC
Loading price history…
Gilead Sciences (GILD) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Gilead Sciences (GILD) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Gilead Sciences (GILD) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Gilead Sciences (GILD) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: GILDIndustry group median
Total Return (1Y)45.69%24.62%
Total Return (3Y, Annualized)35.30%20.37%
Total Return (5Y, Annualized)25.00%-4.02%

Risk Profile

Drawdown History

GILD
GSPC
Loading price history…
Gilead Sciences (GILD) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Gilead Sciences (GILD) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Gilead Sciences (GILD) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: GILDIndustry group median
Volatility (1Y, Annualized)27.57%66.36%
Beta (5Y)0.360.93
Max Drawdown (5Y)-26.59%-80.19%

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. GILD is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

Gilead Sciences (GILD) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: GILDIndustry group median
Sharpe Ratio (1Y)1.500.36
Sortino Ratio (1Y)2.480.58

Profitability

ROE (TTM)

Gilead Sciences (GILD) has negative ROE of -22.45%. That can come from trailing losses or negative book equity, so it is a warning state rather than a clean capital-efficiency measure.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-22.45%

Group distribution
Max
109.18%
Q3
6.23%
GILD
-22.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Largest peers
LLY
86.02%
NVS
24.33%
AZN
22.57%
JNJ
20.02%
MRK
5.06%
GILD
-22.45%
ABBV
--
Loading chart…
Where Gilead Sciences (GILD) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

Gilead Sciences (GILD) has negative net margin of -12.46%. The trailing period ended in a net loss, so the bottom-line conversion read is a warning rather than a profitability strength.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.46%

Group distribution
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
GILD
-12.46%
Min
-17.05%
Largest peers
LLY
31.90%
AZN
17.68%
NVS
17.49%
JNJ
16.20%
ABBV
15.67%
MRK
3.64%
GILD
-12.46%
Loading chart…
Where Gilead Sciences (GILD) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

Gilead Sciences (GILD) turns 42.43% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

42.43%

Group distribution
Max
83.12%
GILD
42.43%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Largest peers
LLY
53.66%
GILD
42.43%
ABBV
39.59%
MRK
35.22%
NVS
34.27%
AZN
29.57%
JNJ
25.74%
Loading chart…
Where Gilead Sciences (GILD) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

Gilead Sciences (GILD) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: GILDIndustry group median
ROE (TTM)-22.45%-26.66%
ROA (TTM)13.47%-12.50%
Net Margin (TTM)-12.46%0.00%
Operating Margin (TTM)42.43%0.00%
Gross Margin (TTM)79.95%37.87%

Growth

Revenue Growth

Gilead Sciences (GILD) grew revenue 2.39%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.

Loading chart…
Gilead Sciences (GILD): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

Gilead Sciences (GILD) grew earnings per share 1,684.21%, above the industry benchmark range. Profits are compounding faster than at any typical peer, though a depressed base year can inflate the percentage, so the level of earnings matters alongside the rate.

Loading chart…
Gilead Sciences (GILD): EPS Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

Growth Metrics

Gilead Sciences (GILD) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: GILDIndustry group median
Revenue Growth (YoY)2.39%11.45%
Revenue Growth (3Y CAGR)2.57%9.94%
EPS Growth (YoY)1,684.21%4.28%
EPS Growth (3Y CAGR)23.04%4.17%

Financial Strength

Current Ratio (MRQ)

Gilead Sciences (GILD) has current ratio of 1.38, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Group distribution
Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GILD
1.38
Min
0.10
Largest peers
LLY
1.39
GILD
1.38
MRK
1.35
JNJ
1.02
AZN
1.01
NVS
0.88
ABBV
0.87
Loading chart…
Where Gilead Sciences (GILD) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

Gilead Sciences (GILD) has debt-to-equity ratio of 2.02, above the industry benchmark range. Debt sits unusually high against shareholders’ equity, leaving the balance sheet more exposed to rate, refinancing, or earnings shocks.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.02

Group distribution
GILD
2.02
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Largest peers
GILD
2.02
NVS
1.29
LLY
1.23
MRK
1.20
AZN
0.66
JNJ
0.55
ABBV
--
Loading chart…
Where Gilead Sciences (GILD) stands on debt-to-equity ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Financial Strength Metrics

Gilead Sciences (GILD) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: GILDIndustry group median
Current Ratio (MRQ)1.385.52
Debt / Equity (MRQ)2.020.15
Net Debt / EBITDA1.251.08

Dividends

Dividend Yield (TTM)

Gilead Sciences (GILD) has dividend yield of 1.94%, above the entire industry range. That headline income is large, but yields this far above peers often come from a falling share price or an at-risk payout, so dividend safety matters more than the percentage itself.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

Group distribution
GILD
1.94%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Largest peers
NVS
2.88%
ABBV
2.40%
MRK
2.29%
GILD
1.94%
JNJ
1.94%
AZN
1.73%
LLY
0.49%
Loading chart…
Where Gilead Sciences (GILD) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

Gilead Sciences (GILD) has payout ratio of 43.46%, above the peer distribution for its industry. The dividend consumes more reported earnings than peers normally do, leaving unusually thin earnings cover.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.46%

Group distribution
GILD
43.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Largest peers
MRK
343.43%
ABBV
117.35%
NVS
90.46%
JNJ
80.12%
AZN
45.38%
GILD
43.46%
LLY
21.71%
Loading chart…
Where Gilead Sciences (GILD) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

Gilead Sciences (GILD) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: GILDIndustry group median
Dividend Yield (TTM)1.94%0.00%
Dividend Payout Ratio (TTM)43.46%0.00%

Valuation

P/E Ratio (TTM)

No usable P/E ratio is available for Gilead Sciences (GILD) this period, so the trailing-earnings valuation read is skipped.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Group distribution
Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
GILD
--
Largest peers
MRK
148.21
ABBV
50.05
LLY
43.95
JNJ
41.92
NVS
31.02
AZN
26.37
GILD
--
Loading chart…
Gilead Sciences (GILD) doesn’t report P/E ratio this period; the box shows the Pharmaceuticals, Biotechnology & Life Sciences group’s distribution and the dots its largest members.

P/S Ratio (TTM)

Gilead Sciences (GILD) trades at 6.68 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Group distribution
Max
58.18
Q3
25.77
Median
7.30
GILD
6.68
Q1
3.01
Min
0.01
Largest peers
LLY
13.95
ABBV
7.80
JNJ
6.69
GILD
6.68
MRK
5.37
NVS
5.35
AZN
4.63
Loading chart…
Where Gilead Sciences (GILD) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

Gilead Sciences (GILD) trades at 15.88 on P/B ratio, above the industry benchmark range. Investors are putting an unusually rich price on each dollar of book equity relative to peers.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.88

Group distribution
GILD
15.88
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Largest peers
LLY
29.96
GILD
15.88
NVS
8.25
JNJ
8.16
MRK
8.06
AZN
5.59
ABBV
-112.34
Loading chart…
Where Gilead Sciences (GILD) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

Gilead Sciences (GILD) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: GILDIndustry group median
P/E Ratio (TTM)--26.69
P/S Ratio (TTM)6.687.30
P/B Ratio (MRQ)15.883.25
Free Cash Flow Yield (TTM)5.16%-1.66%